Equitable Trust’s Quest Diagnostics DGX Stock Holding History

Equitable Trust’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,273	Closed	-$204K	–	281
2019 Q1	$204K	Buy	+2,273	New	+$197K	0.02%	267
2018 Q4	–	Sell	-2,248	Closed	-$243K	–	269
2018 Q3	$243K	Hold	2,248	–	–	0.03%	268
2018 Q2	$247K	Buy	+2,248	New	+$234K	0.03%	234

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Equitable Trust's DGX Position: Q2 2019 in Review

Equitable Trust sold out of Quest Diagnostics (DGX) in Q2 2019, closing a stake of 2,273 shares — an estimated $204K sold.

Equitable Trust first reported a position in DGX in Q2 2018 and held it in 3 quarters. The position peaked at $247K in Q2 2018. 654 funds tracked by Wall St. Rank hold DGX as of Q2 2019.

Equitable Trust reported no remaining Quest Diagnostics position as of Q2 2019 after selling out during the quarter.
Equitable Trust sold 2,273 Quest Diagnostics shares in Q2 2019, an estimated $204K.
Equitable Trust first reported a position in Quest Diagnostics in Q2 2018 and held it in 3 quarters.
Equitable Trust's Quest Diagnostics position peaked at $247K in Q2 2018.
654 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2019.

Based on Equitable Trust's 13F filing for Q2 2019, filed 16 Aug 2019.